COUPLING OF CYTOTOXIC AGENTS TO MONOCLONAL ANTIBODY

我们将向NCI调查人员提供111In抗体放射性标记试剂盒，用于 成像目的。这将使调查人员能够熟悉 并确定使用抗体的可行性 治疗系统中的这些抗体。 我们将提供90Y标记的单抗用于治疗 程序。 我们将开发基于抗体的肿瘤药物递送系统。 目标。 我们将展示药物-半抗原结合物的体外效果。 (即，我们将确定药物活性的保留)。 我们将开发一种基于药物动力学的体内给药系统 不含和含有不同浓度的铟标记药物康乃馨 药物反应性抗体。 我们将展示该递送系统的杀瘤效果。 我们将准备药剂级试剂并提交给NCI人员 用于临床研究。

We shall provide to NCI investigators 111In-antibody radiolabeling kits for imaging purposes. This will permit the investigators to familiarize themselves with the antibodies and to determine the feasibility of using these antibodies in therapeutic systems. We shall provide 90Y labeled monoclonal antibodies for therapeutic programs. We shall develop systems for antibody-based delivery of drugs to tumor targets. We shall demonstrate the in vitro eficacy of the drug-hapten conjugates (i.e., we shall determine retention of drug activity). We shall develop an in vivo delivery system, based on the pharmacokinetics of indium-labeled drug conugate without and with various concentrations of drug reactive antibody. We shall demonstrate tumoricidal efficacy of the delivery system. We shall prepare and submit to NCI personnel pharmaceutical grade reagents for clinical investigations.